Skip to content

Localized colon cancer

TL;DR — Curative-intent colon-cancer treatment starts with en-bloc oncologic resection and reliable pathologic staging. Stage I generally needs surgery alone; stage III benefits from fluoropyrimidine plus oxaliplatin in fit patients, with 10-year MOSAIC overall survival 67.1% versus 59.0% for stage III (André 2015, PMID 26527776). Stage II adjuvant benefit is small on average and concentrated through imperfect risk features; dMMR is favorable prognostically and argues against fluoropyrimidine monotherapy in many settings (Baxter 2022, PMID 34936379). IDEA shows that duration cannot be separated from regimen and T/N risk: 3 months of CAPOX is a common lower-neuropathy option for lower-risk stage III, whereas high-risk disease more often supports 6 months (André 2020, PMID 33271092). Postoperative ctDNA is a powerful recurrence marker; DYNAMIC reduced chemotherapy use from 28% to 15% without worsening 2-year recurrence-free survival in stage II, but assay, timing and escalation utility remain unsettled (Tie 2022, PMID 35657320).

Treatment sequence

Phase Required decision Quality anchor
Preoperative Resectable, obstructed/perforated, synchronous metastasis, hereditary implication Complete staging and multidisciplinary review when complex
Operation Segment, vascular pedicle, mesocolic plane, adjacent-organ involvement En-bloc resection without tumor violation
Pathology pT, pN, margins, nodes, deposits, invasion, budding, MMR Structured report and adequate node search
Adjuvant decision Stage, risk, MMR, fitness, preferences, timing Absolute benefit and toxicity discussion
Surveillance CEA/imaging/colonoscopy by risk and guideline Detect treatable recurrence while limiting burden

Surgery

Oncologic colectomy removes the involved bowel segment with regional lymphovascular drainage and intact mesocolic envelope. Adjacent-organ adherence suspicious for T4b disease should be resected en bloc rather than separated, because inflammatory and malignant adherence cannot be distinguished safely during dissection.

Extent and plane

Complete mesocolic excision (CME) with central vascular ligation formalizes sharp mesocolic-plane dissection and central nodal clearance. Meta-analyses associate CME with higher node yield and possibly improved disease outcomes, but most comparisons are nonrandomized and vulnerable to center/era selection (Kontovounisios 2015, PMID 25283236; Xu 2023, PMID 37414915).

Surgical choice Potential benefit Potential harm/uncertainty
Standard oncologic segmental resection Established balance of clearance and morbidity Technique varies
CME/D3 dissection Better plane and nodal yield Vascular injury and uncertain causal survival gain
Laparoscopic approach Recovery advantages with oncologic equivalence in suitable cases Expertise and bulky/T4 anatomy
Robotic approach Ergonomics and intracorporeal reconstruction Cost and limited evidence of oncologic superiority
Subtotal colectomy Addresses synchronous lesions/high-risk colon Greater bowel-frequency burden

Reviews conclude CME is feasible and increases nodes, while calling for standardized definitions and randomized outcome evidence (Konishi 2022, PMID 35351279; Emmanuel 2016, PMID 26833471). Propensity-matched and pooled studies cannot fully remove surgeon and hospital-volume effects (Giani 2022, PMID 35028735; Anania 2021, PMID 34120270).

Node evaluation

At least 12 examined nodes is a common adequacy target. A systematic review of 61,371 patients found better survival with more nodes in 16/17 studies, with thresholds from 6 to 40 (Chang 2007, PMID 17374833).

Node count is affected by resection, pathology search, patient anatomy, immune response and preoperative treatment. Below 12 should trigger quality review and increases uncertainty in stage II; it is not automatic proof of residual nodal disease.

Stage I

Stage I (T1–2 N0) is usually cured with surgery alone. Selected low-risk T1 cancers removed en bloc endoscopically may avoid colectomy if invasion depth, margins, grade, lymphovascular invasion and budding indicate low nodal risk.

Unfavorable malignant-polyp features include poor differentiation, lymphovascular invasion, high budding, deep submucosal invasion and an involved/indeterminate margin. The decision compares estimated nodal risk with operative risk.

Stage II risk

Risk feature Why it matters Limitation
T4 Strong recurrence-risk feature T4a and T4b differ
<12 nodes Understaging/quality concern Node count is not purely causal
Obstruction/perforation Aggressive/emergency presentation Definitions vary
Lymphovascular/perineural invasion Dissemination potential Reporting variability
Poor differentiation Adverse morphology Less adverse in some dMMR tumors
High tumor budding Invasive phenotype Scoring reproducibility
Positive/close margin Residual-disease risk Requires surgical-pathology review

QUASAR randomized mostly stage II colorectal patients to fluorouracil/folinic acid or observation and found a small absolute survival benefit, approximately 3.6% at 5 years under the study assumptions (QUASAR Collaborative Group 2007, PMID 18083404). Modern decisions must account for improved surgery, stage migration and molecular risk.

ASCO recommends against routine adjuvant chemotherapy for low-risk stage II and supports offering it for T4 or considering it for other high-risk features; oxaliplatin is not routinely required and should be a shared decision (Baxter 2022, PMID 34936379).

MMR in stage II

dMMR/MSI-high stage II tumors generally have favorable prognosis and limited evidence of benefit from fluoropyrimidine monotherapy. MMR must be interpreted alongside T4 and other risk; it is not a universal instruction to omit all chemotherapy.

MOSAIC subgroup analyses were underpowered for definitive interaction claims, illustrating why retrospective biomarker subsets should not overrule the total evidence (André 2015, PMID 26527776).

Stage III adjuvant therapy

MOSAIC randomized FOLFOX4 versus fluorouracil/leucovorin. At 10 years, stage III overall survival was 67.1% versus 59.0%, establishing durable oxaliplatin benefit; stage II did not show an overall-survival advantage (André 2015, PMID 26527776).

CAPOX and FOLFOX are standard oxaliplatin backbones. Selection depends on renal function, oral-adherence reliability, infusion access, dosing schedule and toxicity profile.

Direct randomized comparison of CAPOX and modified FOLFOX6 in operated high-risk stage II/stage III populations did not establish a universal efficacy winner; schedule, toxicity and treatment delivery remain practical selectors (Pectasides 2015, PMID 25956750).

Regimen Advantages Distinct burdens
CAPOX Fewer infusion visits; 3-month evidence in lower-risk stage III Hand-foot syndrome, diarrhea, renal dosing, oral adherence
FOLFOX Infusional schedule familiar; usable when capecitabine unsuitable Port/pump, more visits, mucositis/cytopenias
Fluoropyrimidine alone Lower neurotoxicity Lower efficacy in fit stage III; used when oxaliplatin unsuitable

Duration: IDEA

IDEA pooled six randomized trials comparing 3 versus 6 months. Overall noninferiority narrowly was not established, but regimen and risk produced clinically meaningful heterogeneity (André 2020, PMID 33271092).

Group Common interpretation Neuropathy tradeoff
T1–3 N1 with CAPOX 3 months often reasonable Much less cumulative oxaliplatin exposure
T4 and/or N2 6 months more often favored More persistent neuropathy
FOLFOX 6 months retains stronger efficacy support Duration decision individualized

IDEA-France and HORG results demonstrate that individual trials and regimens did not produce identical estimates (André 2018, PMID 29620995; Souglakos 2019, PMID 31228203). ASCO’s duration guideline therefore frames a risk- and regimen-specific discussion (Lieu 2019, PMID 30986117).

TOSCA safety/compliance results also showed how cumulative exposure changes treatment completion and neurotoxicity, not only disease-free survival (Lonardi 2016, PMID 27573560). Real-world cohorts after adoption of shorter CAPOX report patient-reported as well as survival outcomes, but are subject to era and selection effects (Franken 2024, PMID 39024724).

Toxicity and fitness

Oxaliplatin neuropathy is cumulative and can persist years. Fluoropyrimidines cause diarrhea, mucositis, myelosuppression, hand-foot syndrome and uncommon but serious cardiotoxicity. DPD deficiency can cause catastrophic fluoropyrimidine toxicity; prospective DPYD genotype-guided dosing reduced severe toxicity in variant carriers (Henricks 2018, PMID 30348537).

Adjuvant therapy treats microscopic risk, not measurable disease. Competing mortality, frailty, neuropathy, renal function and patient priorities therefore matter more than chronologic age alone.

Timing

Adjuvant therapy is generally started after surgical recovery, ideally without avoidable delay. Observational data associate longer delay with worse outcomes, but illness causing delay also predicts prognosis. Anastomotic leak, infection and deconditioning require stabilization rather than unsafe calendar adherence.

ctDNA-guided treatment

Postoperative ctDNA identifies molecular residual disease before radiographic recurrence in many patients. DYNAMIC randomized stage II patients to ctDNA-guided versus standard management: chemotherapy use fell from 28% to 15%; 2-year recurrence-free survival was 93.5% versus 92.4%, meeting noninferiority (Tie 2022, PMID 35657320).

Five-year DYNAMIC follow-up supports durable de-escalation in that setting, but ctDNA-negative recurrence and assay differences remain (Tie 2025, PMID 40055522). DYNAMIC-III tested ctDNA-guided escalation/de-escalation in stage III, underscoring that prognostic enrichment does not guarantee benefit from more intensive treatment (Tie 2025, PMID 41115959).

ctDNA question Status
Is postoperative positivity prognostic? Strongly supported
Can negative stage II result reduce chemotherapy? Randomized DYNAMIC evidence
Does escalation clear ctDNA and improve survival? Not uniformly established
Which assay/timing is best? Unresolved
Should serial surveillance replace imaging? No

CIRCULATE-Japan combines observational GALAXY with randomized VEGA/ALTAIR platform questions, illustrating the adaptive evidence model (Taniguchi 2021, PMID 33931919). Large observational MRD analyses show strong recurrence discrimination but remain vulnerable to lead-time and treatment-selection bias (Nakamura 2024, PMID 39284954).

Neoadjuvant colon therapy

Preoperative systemic therapy can treat micrometastatic disease early and test chemosensitivity, particularly in radiologically advanced T3/T4 colon cancer. Risks include inaccurate clinical staging, progression, obstruction and surgical delay.

Randomized-trial meta-analysis suggests neoadjuvant chemotherapy improves pathologic downstaging and may improve disease outcomes without clearly increasing perioperative harm, but regimen and selection remain unsettled (Noronha 2025, PMID 40306117). dMMR tumors may respond differently to chemotherapy and are a major neoadjuvant immunotherapy research population.

Surveillance after curative treatment

Surveillance combines clinical review, CEA, CT and colonoscopy. Its goal is detection of recurrence or metachronous neoplasia amenable to treatment—not merely earlier knowledge.

Intensive versus minimal surveillance trials show more recurrences detected for curative-intent treatment, but overall-survival gains are small/inconsistent. Colonoscopy addresses metachronous neoplasia rather than most distant recurrence (Kahi 2016, PMID 26892199).

Open questions

  • Which ctDNA-positive patients benefit from escalation rather than merely having poor prognosis? (Tie 2025, PMID 41115959)
  • Can ctDNA-negative high-risk stage II patients safely omit chemotherapy across assays? (Tie 2022, PMID 35657320)
  • Which radiologic T3/T4 colon tumors benefit from neoadjuvant therapy? (Noronha 2025, PMID 40306117)
  • Does CME improve cancer-specific survival independent of center and stage migration? (Xu 2023, PMID 37414915)
  • How should persistent neuropathy be weighted against small absolute duration benefits? (André 2020, PMID 33271092)

References

  1. André T, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015;33(35):4176-87. PMID 26527776
  2. Baxter NN, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022;40(8):892-910. PMID 34936379
  3. André T, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020;21(12):1620-1629. PMID 33271092
  4. Tie J, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022;386(24):2261-2272. PMID 35657320
  5. Kontovounisios C, et al. Complete mesocolic excision in colorectal cancer: a systematic review. Colorectal Dis. 2015;17(1):7-16. PMID 25283236
  6. Xu J, et al. Complete mesocolic excision versus standard resection for colon cancer: a systematic review and meta-analysis of perioperative safety and an evaluation of the use of a robotic approach. Tech Coloproctol. 2023;27(11):995-1005. PMID 37414915
  7. Konishi T, You YN. Complete Mesocolic Excision and Extent of Lymphadenectomy for the Treatment of Colon Cancer. Surg Oncol Clin N Am. 2022;31(2):293-306. PMID 35351279
  8. Emmanuel A, Haji A. Complete mesocolic excision and extended (D3) lymphadenectomy for colonic cancer: is it worth that extra effort? A review of the literature. Int J Colorectal Dis. 2016;31(4):797-804. PMID 26833471
  9. Giani A, et al. Mid-term oncological outcomes after complete versus conventional mesocolic excision for right-sided colon cancer: a propensity score matching analysis. Surg Endosc. 2022;36(9):6489-6496. PMID 35028735
  10. Anania G, et al. Right hemicolectomy with complete mesocolic excision is safe, leads to an increased lymph node yield and to increased survival: results of a systematic review and meta-analysis. Tech Coloproctol. 2021;25(10):1099-1113. PMID 34120270
  11. Chang GJ, et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99(6):433-41. PMID 17374833
  12. Quasar Collaborative Group, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020-9. PMID 18083404
  13. Pectasides D, et al. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. BMC Cancer. 2015;15:384. PMID 25956750
  14. André T, et al. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. J Clin Oncol. 2018;36(15):1469-1477. PMID 29620995
  15. Souglakos J, et al. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. Ann Oncol. 2019;30(8):1304-1310. PMID 31228203
  16. Lieu C, et al. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(16):1436-1447. PMID 30986117
  17. Lonardi S, et al. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol. 2016;27(11):2074-2081. PMID 27573560
  18. Franken IA, et al. Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months. Eur J Cancer. 2024;208:114207. PMID 39024724
  19. Henricks LM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459-1467. PMID 30348537
  20. Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31(5):1509-1518. PMID 40055522
  21. Tie J, et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nat Med. 2025;31(12):4291-4300. PMID 41115959
  22. Taniguchi H, et al. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112(7):2915-2920. PMID 33931919
  23. Nakamura Y, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30(11):3272-3283. PMID 39284954
  24. Noronha MM, et al. Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis of randomized controlled trials. Eur J Cancer. 2025;222:115476. PMID 40306117
  25. Kahi CJ, et al. Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016;150(3):758-768.e11. PMID 26892199